Lexaria Bioscience Received Notice of Delisting

Lexaria Bioscience (LEXX) received a delisting notice from Nasdaq on August 4, 2026, due to non-compliance with the $1.00 minimum bid price rule. The company has requested a hearing, which temporarily stays the delisting. Following an August 3 reverse stock split, LEXX's stock price is now above $1.00, and the company anticipates regaining compliance and remaining listed on Nasdaq.